Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Feature|Articles|August 26, 2026
Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations
Author(s)Raviv Pryluk
Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk.
Advertisement
Advertisement
Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your biostatistician pulls up a standard power calculation, someone picks an effect size that feels reasonable, say, a 30% improvement over placebo, and the software produces a sample size. The meeting ends. The number gets locked in.
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Advertisement
Advertisement